

1 **Supplementary Table S3.** Table showing the epitope (red) of botensilimab, ipilimumab and
 2 tremelimumab on human CTLA-4.

Antibody	Human CTLA-4 Epitope	Reference
Botensilimab	KAMHVAQPAVVLAGSRGIASFVCEYASPGKATEVRVTVLRQADS <u>QVTEVC</u> AATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELM <u>YP</u> <u>PPYYLGI</u> GNGTQIYVIDP	34*
Ipilimumab	KAMHVAQPAVVLAGSRGIASFVCEYASPGKATE <u>EV</u> RVTVLRQAD <u>SQVTEVC</u> AATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICK <u>VELM</u> <u>YP</u> <u>PPYYLGI</u> GNGTQIYVIDP	35
Tremelimumab	KAMHVAQPAVVLAGSRGIASFVCEYASPGKATE <u>EV</u> <u>R</u> VTVLRQAD <u>SQVTEVC</u> AATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTG <u>LYIC</u> <u>VELM</u> <u>YP</u> <u>PPYYLGI</u> GNGTQIYVIDP	36

3 *Botensilimab contains the same variable regions as AGEN1884. Epitope highlighted in red.

4 Source: ³⁴[Gombos et al., 2018](#); ³⁵[Ramagopal et al., 2017](#); ³⁶[Lee et al., 2016](#).